These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 28243883

  • 1. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
    Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R.
    Arch Osteoporos; 2017 Dec; 12(1):22. PubMed ID: 28243883
    [Abstract] [Full Text] [Related]

  • 2. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI, Durden E, Limone B, Radbill L, Juneau PL, Spangler L, Mirza FM, Stolshek BS.
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [Abstract] [Full Text] [Related]

  • 3. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.
    Singer AJ, Liu J, Yan H, Stad RK, Gandra SR, Yehoshua A.
    Osteoporos Int; 2021 Dec; 32(12):2473-2484. PubMed ID: 34095966
    [Abstract] [Full Text] [Related]

  • 4. Persistence with denosumab and zoledronic acid among older women: a population-based cohort study.
    Tremblay É, Perreault S, Dorais M.
    Arch Osteoporos; 2016 Dec; 11(1):30. PubMed ID: 27679503
    [Abstract] [Full Text] [Related]

  • 5. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
    Lee S, Glendenning P, Inderjeeth CA.
    Osteoporos Int; 2011 Mar; 22(3):741-53. PubMed ID: 20589368
    [Abstract] [Full Text] [Related]

  • 6. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
    Modi A, Sajjan S, Insinga R, Weaver J, Lewiecki EM, Harris ST.
    Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
    [Abstract] [Full Text] [Related]

  • 7. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T, Boyanov M, Shinkov A, Petkova R, Intorcia M, Psachoulia E.
    Arch Osteoporos; 2017 Dec 21; 13(1):1. PubMed ID: 29264666
    [Abstract] [Full Text] [Related]

  • 8. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.
    Hadji P, Kyvernitakis I, Kann PH, Niedhart C, Hofbauer LC, Schwarz H, Kurth AA, Thomasius F, Schulte M, Intorcia M, Psachoulia E, Schmid T.
    Osteoporos Int; 2016 Oct 21; 27(10):2967-78. PubMed ID: 27172934
    [Abstract] [Full Text] [Related]

  • 9. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P, Papaioannou N, Gielen E, Feudjo Tepie M, Zhang E, Frieling I, Geusens P, Makras P, Resch H, Möller G, Kalouche-Khalil L, Fahrleitner-Pammer A.
    Osteoporos Int; 2015 Oct 21; 26(10):2479-89. PubMed ID: 26018090
    [Abstract] [Full Text] [Related]

  • 10. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
    Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T.
    Osteoporos Int; 2012 Jan 21; 23(1):223-31. PubMed ID: 21308365
    [Abstract] [Full Text] [Related]

  • 11. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
    Fahrleitner-Pammer A, Papaioannou N, Gielen E, Feudjo Tepie M, Toffis C, Frieling I, Geusens P, Makras P, Boschitsch E, Callens J, Anastasilakis AD, Niedhart C, Resch H, Kalouche-Khalil L, Hadji P.
    Arch Osteoporos; 2017 Dec 21; 12(1):58. PubMed ID: 28643265
    [Abstract] [Full Text] [Related]

  • 12. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis.
    Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Ström O.
    Osteoporos Int; 2015 Oct 21; 26(10):2401-11. PubMed ID: 26282229
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA, Amonkar MM, Hebborn A, Altman R.
    Curr Med Res Opin; 2005 Sep 21; 21(9):1453-60. PubMed ID: 16197664
    [Abstract] [Full Text] [Related]

  • 16. Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program.
    Papaioannou A, Khan A, Belanger A, Bensen W, Kendler D, Theoret F, Amin M, Brekke L, Erdmann M, Walker V, Adachi JD.
    Curr Med Res Opin; 2015 Sep 21; 31(7):1391-401. PubMed ID: 25993017
    [Abstract] [Full Text] [Related]

  • 17. Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database.
    Li L, Roddam A, Gitlin M, Taylor A, Shepherd S, Shearer A, Jick S.
    Menopause; 2012 Jan 21; 19(1):33-40. PubMed ID: 21926926
    [Abstract] [Full Text] [Related]

  • 18. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.
    Devine J, Trice S, Finney Z, Yarger S, Nwokeji E, Linton A, Davies W.
    Osteoporos Int; 2012 Apr 21; 23(4):1415-24. PubMed ID: 21786005
    [Abstract] [Full Text] [Related]

  • 19. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
    Yusuf AA, Cummings SR, Watts NB, Feudjo MT, Sprafka JM, Zhou J, Guo H, Balasubramanian A, Cooper C.
    Arch Osteoporos; 2018 Mar 21; 13(1):33. PubMed ID: 29564735
    [Abstract] [Full Text] [Related]

  • 20. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
    Moshi MR, Nicolopoulos K, Stringer D, Ma N, Jenal M, Vreugdenburg T.
    Calcif Tissue Int; 2023 Jun 21; 112(6):631-646. PubMed ID: 37016189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.